MAPK3 and triple-A syndrome: This supposition is in line with our previous observations where the reduced activity of oxidative stress-related mediators such as NFκB and ERK1/2 as well as inhibition of MMP9 was found in AAA patients after simvastatin administration [15, 43, 44].